COMPANIES COVERED
Bluebird bio, Inc.Download FREE Report Sample
Download Free sampleThalassemia?is a blood disorder passed down through families (inherited) in which the body makes an abnormal form or inadequate amount of hemoglobin. Hemoglobin is the protein in red blood cells that carries oxygen. The disorder results in large numbers of red blood cells being destroyed, which leads to anemia.
Thalassemia Market contains market size and forecasts of Thalassemia in Global, including the following market information:
Global Thalassemia Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Thalassemia market was valued at 3101.8 million in 2021 and is projected to reach US$ 5359.1 million by 2028, at a CAGR of 8.1% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Iron Chelating Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Thalassemia include Bluebird bio, Inc., Acceleron Pharma, Inc., Celgene Corporation, GlaxoSmithKline plc, Incyte Corporation, Gamida Cell, Kiadis Pharma, La Jolla Pharmaceutical Company and IONIS Pharmaceuticals. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Thalassemia companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Thalassemia Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Thalassemia Market Segment Percentages, by Type, 2021 (%)
Iron Chelating Drugs
Others
Global Thalassemia Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Thalassemia Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Research Institute
Laboratories
Others
Global Thalassemia Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Thalassemia Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Thalassemia revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Thalassemia revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bluebird bio, Inc.
Acceleron Pharma, Inc.
Celgene Corporation
GlaxoSmithKline plc
Incyte Corporation
Gamida Cell
Kiadis Pharma
La Jolla Pharmaceutical Company
IONIS Pharmaceuticals
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
